Xilio Therapeutics (XLO) Total Current Liabilities (2020 - 2026)

Xilio Therapeutics has disclosed Total Current Liabilities across 7 years of filings, most recently posting $43.0 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $43.0 million, down 9.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $43.0 million (down 9.82% YoY), and the FY2025 annual result was $56.3 million, up 106.42% from the prior year.
• Total Current Liabilities came in at $43.0 million for Q1 2026 at Xilio Therapeutics, down from $56.3 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $56.4 million in Q3 2025 to a low of $12.2 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $27.3 million (2024), against an average of $30.9 million.
• Across the five-year window, Total Current Liabilities decreased 24.44% in 2023 and jumped 137.16% in 2024, its largest moves.
• Xilio Therapeutics' Total Current Liabilities stood at $21.1 million in 2022, then fell by 24.44% to $16.0 million in 2023, then surged by 70.84% to $27.3 million in 2024, then jumped by 106.42% to $56.3 million in 2025, then declined by 23.66% to $43.0 million in 2026.
• The last three Total Current Liabilities figures came in at $43.0 million (Q1 2026), $56.3 million (Q4 2025), and $56.4 million (Q3 2025), per Business Quant data.